Want to see FR:ALMIB full AI Analyst Report?
ALMIB Stock Chart & Stats
€0.67
<€0.01(0.15%)
At close: 4:00 PM EDT
€0.67
<€0.01(0.15%)
Day’s Range― - ―
52-Week Range€0.62 - €1.20
Previous CloseN/A
Volume48.65K
Average Volume (3M)268.33K
Market Cap
€55.69M
Enterprise Value€67.72M
Total Cash (Recent Filing)€4.72M
Total Debt (Recent Filing)€12.24M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding77,817,220
10 Day Avg. Volume303,333
30 Day Avg. Volume268,330
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Bulls Say, Bears Say
Bulls Say
Proprietary Willaertia Magna PlatformAmoéba’s proprietary Willaertia magna platform is a durable competitive asset: it creates differentiated biological actives that target crop protection and plant health, supports product exclusivity, and underpins multiple application pathways. Over months this core IP can sustain product differentiation and licensing leverage versus commodity chemical inputs.
Multiple Scalable Revenue ChannelsThe firm's business model includes direct product sales plus licensing, milestones, royalties and contracted R&D. Licensing and partner commercialization are capital-light routes to scale and can provide recurring, royalty-style revenue and milestone payments, offering durable optionality while industrial production is scaled.
Signs Of Operational Improvement In 2025Reported narrowing losses and a 2025 improvement in free cash flow suggest operating trends may be stabilizing. If sustained, this reduces near-term funding needs, improves runway dynamics and supports incremental progress toward commercial scale; it's a structural early recovery signal rather than a one-off market movement.
Bears Say
Revenue Collapsed To Zero In 2025A complete collapse of reported revenue in 2025 is a severe structural problem: it signals failure to commercialize products at scale or to maintain distributor/partner sales, undermining unit economics and market credibility. Without recurrent product revenues, the firm cannot fund fixed costs or validate margins over the coming quarters.
Negative Equity And Higher LeverageThree consecutive years of negative equity and a large increase in debt materially weaken financial flexibility. Elevated leverage increases refinancing and covenant risk, raises financing costs, and can constrain strategic choices (partnerships, capital spending). This is a durable constraint on execution absent recapitalization.
Persistent Negative Operating Cash FlowConsistent negative operating cash flow and free cash flow create ongoing external funding needs. Persistent cash burn threatens R&D, regulatory filings and industrialization investments required to commercialize biological products, forcing dilution or costly debt and limiting the company’s ability to execute medium-term commercialization plans.
Amoeba SA News
ALMIB FAQ
What was Amoeba SA’s price range in the past 12 months?
Amoeba SA lowest stock price was €0.62 and its highest was €1.20 in the past 12 months.
What is Amoeba SA’s market cap?
Amoeba SA’s market cap is €55.69M.
When is Amoeba SA’s upcoming earnings report date?
Amoeba SA’s upcoming earnings report date is Sep 24, 2026 which is in 49 days.
How were Amoeba SA’s earnings last quarter?
Amoeba SA released its earnings results on Mar 26, 2026. The company reported -€0.066 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.066.
Is Amoeba SA overvalued?
According to Wall Street analysts Amoeba SA’s price is currently Overvalued.
Does Amoeba SA pay dividends?
Amoeba SA does not currently pay dividends.
What is Amoeba SA’s EPS estimate?
Amoeba SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amoeba SA have?
Amoeba SA has 77,817,220 shares outstanding.
What happened to Amoeba SA’s price movement after its last earnings report?
Amoeba SA reported an EPS of -€0.066 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.112%.
Which hedge fund is a major shareholder of Amoeba SA?
Currently, no hedge funds are holding shares in FR:ALMIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Amoeba SA
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across various fields. These applications are designed to mitigate biological risks in critical areas like water purification, the treatment of human injuries, and safeguarding agricultural crops. Established in 2010, Amoéba S.A. is based in Chassieu, France.